2023 World Conference on Lung Cancer (Posters)-EP12.01. Association of CYP450 and Drug Efflux Transporters Polymorphism Influence Outcomes of Thai Non-small Cell Lung Cancer Treated with Osimertinib

EP12.01. Association of CYP450 and Drug Efflux Transporters Polymorphism Influence Outcomes of Thai Non-small Cell Lung Cancer Treated with Osimertinib - PDF(Abstract)

Back to course

Pdf Summary

This study looked at the association between certain genetic variations and the outcomes of patients with non-small cell lung cancer (NSCLC) who were treated with the targeted therapy drug osimertinib. The researchers evaluated single nucleotide polymorphisms (SNPs) of various genes involved in drug metabolism and transport, including ABCB1, ABCG2, CYP1A2, CYP2A6, CYP2C9, CYP3A4, CYP3A5, and POR. They assessed the associations between these SNPs and objective response rate (ORR), incidence of adverse drug reactions (ADRs), median progression-free survival (PFS), and median time to treatment failure (TTF) using various statistical tests.<br /><br />The study included 63 Thai patients with NSCLC. The majority of the patients had EGFR mutations, and the most common mutation was the exon 19 deletion. The researchers found that certain genetic variations, including ABCG2 rs2231164 C/C, ABCG2 rs4148157 A/A, and CYP2A6 non*4/*4 genotypes, were associated with an increased incidence of ADRs, leading to a high frequency of dose reduction in the study population. Additionally, CYP3A5 rs776746 *3/*3 genotype was associated with an increased ORR, while CYP2C9 rs1057910 C/C genotype was associated with an increased incidence of ADRs and a decreased TTF and PFS.<br /><br />The study concluded that specific genetic variations were associated with an increased risk of ADRs and ORR, but a decreased PFS and TTF in Thai NSCLC patients treated with osimertinib. The researchers noted that the allele frequency of certain genetic variations differed between ethnic groups and may contribute to the differences in ADR incidence observed in their study compared to previous clinical trials. The findings suggest that genetic differences among patients may impact treatment outcomes and the frequency of dose adjustments in NSCLC patients receiving osimertinib.

Asset Subtitle

Teerapat Majam

Meta Tag

Speaker Teerapat Majam

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

genetic variations

non-small cell lung cancer

NSCLC

osimertinib

SNPs

drug metabolism

drug transport

adverse drug reactions

PFS

TTF